Insulin resistance is a key feature of metabolic syndrome and is associated with dyslipidaemia, hypertension and diabetes. Indeed, insulin resistance is a good predictor of metabolic syndrome. The interconnection between each of these conditions is now being established, for example hypertensive patients often have insulin resistance and it is possible to show that patients with hypertension have hyperinsulinaemia more frequently than normotensive subjects. 1 Hypertensive patients also tend to have more visceral fat than normotensives, leading to the suggestion that visceral adiposity may play a key role in insulin resistance. It has been shown that visceral fat correlates significantly with insulin sensitivity, measured as insulin-induced glucose uptake, whereas subcutaneous fat does not. 2 Although there is a positive correlation between intraabdominal fat and the number of components of metabolic syndrome. 3 Therefore, visceral obesity, which is closely related to insulin resistance, should play a major role in metabolic syndrome. Taken together, visceral obesity induces dyslipidaemia, hypertension, diabetes, endothelial dysfunction, prothrombosis, enhanced inflammatory reaction and renal hyperperfusion -all risk factors for cardiovascular disease. Thus, metabolic syndrome is a major cardiovascular risk factor.
Metabolic syndrome -a cardiovascular risk factor
Insulin resistance is a key feature of metabolic syndrome and is associated with dyslipidaemia, hypertension and diabetes. Indeed, insulin resistance is a good predictor of metabolic syndrome. The interconnection between each of these conditions is now being established, for example hypertensive patients often have insulin resistance and it is possible to show that patients with hypertension have hyperinsulinaemia more frequently than normotensive subjects. 1 Hypertensive patients also tend to have more visceral fat than normotensives, leading to the suggestion that visceral adiposity may play a key role in insulin resistance. It has been shown that visceral fat correlates significantly with insulin sensitivity, measured as insulin-induced glucose uptake, whereas subcutaneous fat does not. 2 Although there is a positive correlation between intraabdominal fat and the number of components of metabolic syndrome. 3 Therefore, visceral obesity, which is closely related to insulin resistance, should play a major role in metabolic syndrome. Taken together, visceral obesity induces dyslipidaemia, hypertension, diabetes, endothelial dysfunction, prothrombosis, enhanced inflammatory reaction and renal hyperperfusion -all risk factors for cardiovascular disease. Thus, metabolic syndrome is a major cardiovascular risk factor.
The role of the renin-angiotensin system
There is growing evidence indicating that adipocytes produce several cytokines, so-called adipokines, such as leptin, tumour necrosis factor alpha (TNF-α), non-esterified fatty acid (NEFAs), prostaglandins, adiponection, resistin, angio-tensinogen, interleukin-1 (IL-1), interleukin-6 (IL-6), and plasminogen activator inhibitor type 1 (PAI-1). Angiotensinogen is a key substance influencing endothelial function and 
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Renin cardiovascular disease. A recent study showed that a high fat diet upregulated angiotensinogen gene expression in visceral fat but not in subcutaneous fat. 4 Another study showed that components of the renin-angiotensin system (RAS) are elevated in obese people but they decrease with weight loss. 5 Therefore, the RAS may play an important role in the development of cardiovascular disease and metabolic syndrome. Accordingly, weight reduction with bariatric surgery can reduce insulin resistance in severely obese patients. 6 In contrast, moderate reduction of subcutaneous fat with liposuction does not decrease visceral fat nor improve insulin resistance in obese patients. 7 Thus, visceral adiposity plays an important role in the development of insulin resistance.
Angiotensin II (Ang II), a component of the RAS, is a well known stimulant of reactive oxygen species (ROS) generation, mainly through the activation of nicotinamide-adenine (dinucleotide) phosphate (NAD[P]H) oxidase. To evaluate the mechanism of Ang II-induced insulin resistance, we studied the effect of a two-week Ang II infusion on insulin sensitivity in rats using the hyperinsulinaemic euglycaemic glucose clamp method. Both the glucose infusion rate and insulin-induced glucose uptake into the muscle were markedly decreased. 8 Thus, chronic administration of Ang II caused insulin resistance in muscle and adipose tissues. In the Ang II-infused rats the plasma level of lipid peroxide, a marker of oxidative stress, was also increased. Additionally, tempol (a membranepermeable superoxide dismutase mimetic) reversed the Ang II-induced decrease in glucose infusion rate and glucose uptake in isolated skeletal muscle. 9 Thus, oxidative stress may play an important role in Ang II-induced insulin resistance. Indeed, it has been reported that Ang II-induced ROS upregulation affects several parts of the intracellular insulin signaling pathways. In vitro, ROS impairs insulin receptor substrate-1 (IRS-1) phophorylation and IRS-1-induced phosphatidylinositol 3-kinase (PI3-kinase) activation in cultured adipocytes, leading to the impaired translocation of glucose transporter 4 (GLUT-4) into the membrane, resulting in insulin resistance. 10 Therefore, treatment with drugs that block the RAS may improve insulin resistance, possibly through the inhibition of oxidative stress and the improvement of beta-cell
Additionally, there are several putative effects of RAS blockers on carbohydrate metabolism. These include the inhibition of oxidative stress production, inhibition of sympathetic activity, prevention of hypokalaemia and improvement in the microcirculation of muscles and the pancreas, decrease in free fatty acid, increase in adiponectin and change in muscle fibre composition. Accordingly, there are several large-scale clinical trials indicating that RAS blockers, such as angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) could prevent the onset of new diabetes in hypertensive patients. Therefore, agents that suppress the RAS could be beneficial in hypertensive patients with metabolic syndrome.
Counteracting effect of adrenomedullin to Ang II
In addition to angiotensinogen, adipocytes produce several adipokines which potentially decrease insulin sensitivity; such as TNF-α, resistin, leptin and NEFAs. Adipocytes also secrete adiponectin and adrenomedullin, two hormones which increase insulin sensitvity. In contrast to Ang II, adrenomedullin inhibits oxidative stress production. 11 An infusion of Ang II induced more severe insulin resistance in adrenomedullin-deficient mice than in wild-type mice, 12 suggesting a counteracting effect of endogenous adrenomedullin to Ang II. Additonally, older adrenomedullin deficient mice exhibit insulin resistance in muscle, possibly through over production of ROS, which is not observed in young mice, 13 which may be explained by advancing age causing oxidative stress to be accumulated through overproduction of ROS. This is supported by data showing that treatment with tempol normalised impaired glucose uptake into the muscle in both Ang IIinfused rats 12 and older adrenomedullin-deficient mice. 13 In adrenomedullin-deficient mice, the administration of Ang II, 11 hypoxia 14 and arterial cuff injury, 15 all of which produce oxidative stress, can induce severe coronary arterial sclerosis, pulmonary arterial hyperplasia and arterial intimal hyperplasia, respectively.
Link between hypertension and insulin resistance
Although the mechanism for the development of hypertension induced by insulin resistance is still unknown, there is a plausible hypothesis that insulin resistance is present in muscle, adipose tissues and the liver, but not in the kidney or the sympathetic nervous system. Hyperinsulinaemia causes salt retention and sympathetic overactivity resulting in increased blood pressure as insulin can increase sodium reabsorption in the proximal tubules and stimulate sympathetic tone. A recent study supported this hypothesis, which showed that insulin increases sodium bicarbonate reabsorption in the proximal tubules of wild-type and IRS-1 deficient mice, but not in those of IRS-2 deficient mice. 16 The IRS-1 deficient mice exhibited higher blood pressure than the IRS-2 deficient mice, possibly through greater sodium retention. Thus, insulin resistance occurs in muscle, which is attributable to the derangements of IRS-1. In turn, hyper-insulinaemia induces sodium retention via IRS-2 phosphorylation in the kidney, resulting in volume-dependent, salt-sensitive hypertension (Figure 1) . Additionally, Ang II directly stimulates sodium reabsorption in the proximal tubule. 17 Accordingly, obese patients with metabolic syndrome often exhibit salt-sensitive hypertension, 18 the characteristics of which are features of metabolic syndrome: obesity, insulin resistance, low high-density lipoprotein (HDL) cholesterol, microalbuminuria and intraglomerular hypertension.
Relationship between salt, insulin resistance and hypertension
There is an intimate relationship between saltsensitivity and insulin sensitivity in hypertensive patients. 19 A high salt diet not only increases blood pressure 20 but also decreases insulin sensitivity, possibly through overproduction of oxidative stress. 21 A Finish epidemiological study showed that the prevalence of diabetes increases in people with a high salt diet. 22 In contrast, potassium supplementation in salt-sensitive hypertensive patients inhibited salt-induced elevation of blood pressure 23, 24 as well as improved salt-induced insulin resistance, through the inhibition of ROS production. 21 Furthermore, the Dietary Approaches to Stop Hypertension (DASH) diet, a vegetables and fruit diet which is rich in potassium, decreases blood pressure and fasting blood sugar. 25 There is some evidence that potassium acts as an antioxidant. Thus, in saltsensitive hypertensive rats dietary salt decreases insulin sensitivity and potassium increases insulin
Spotlight on Renin
Renin Report In Dahl-salt-sensitive rats, high salt intake increased ROS production in the heart inducing cardiac diastolic dysfunction, which was normalised by potassium supplementation through the inhibition of ROS production. 26 Thus, dietary salt and potassium stimulate and inhibit ROS production, respectively. ROS may also be involved not only in the development of insulin resistance but also in the development of cardiac dysfunction and atherosclerosis in salt-sensitive hypertensive people and animals. Figure 2 shows the factors influencing insulin sensitivity. Dietary salt and Ang II released from visceral fats can induce insulin resistance in muscle and adipose tissue through over production of ROS. In contrast, potassium and adrenomedullin improve insulin resistance by inhibiting ROS production. Visceral adiposity, which produces angiotensinogen, is involved in the development of insulin resistance in metabolic syndrome. With the absence of insulin resistance in the kidney, both hyperinsulinaemia and increased Ang II causes sodium retention, by stimulating sodium reabsorption in the proximal tubules, resulting in salt-sensitive hypertension. Thus, the RAS plays an important role in insulin sensitivity and salt-sensitivity in obese patients with metabolic syndrome. 
Salt-sensitive hypertension
